Followers | 2 |
Posts | 34 |
Boards Moderated | 0 |
Alias Born | 06/06/2017 |
Tuesday, June 06, 2017 4:43:14 PM
TWST: When you say rational design, what do you mean by that?
Mrs. King: As contrasted to screening approaches where some people select small molecules by screening millions of compounds against the target, in our case what we are doing instead is understanding the native interaction and how the normal biology works, and then creating a molecule that will interact with that particular target. We are rationally designing it.
Recent GLYC News
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/15/2024 09:01:27 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/14/2024 08:13:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:00:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 07:55:22 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/29/2024 11:24:49 PM
- GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan • Business Wire • 07/25/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 01:30:15 PM
- GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) • Business Wire • 06/04/2024 11:00:00 AM
- GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 • Business Wire • 05/29/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:01:01 PM
- GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) • Business Wire • 05/06/2024 10:00:00 AM
- GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 • Business Wire • 04/25/2024 11:00:00 AM
- GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 • Business Wire • 03/27/2024 11:00:00 AM
- GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 • Business Wire • 03/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 02:16:05 PM
- GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference • Business Wire • 02/26/2024 12:00:00 PM
- GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 02/12/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 09:05:12 PM
- GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687 • Business Wire • 01/04/2024 12:00:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM